All In MedTech

Device Trial Radar · NCT05526560

Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

A Prospective, Global Study Designed to Collect Real-world Clinical Outcomes of the MITRIS RESILIA Mitral Valve

Last checked: Nov 20, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

504

Actual

Start

Jan 11, 2023

Primary completion

Jan 2028

Study completion Dec 2035

Sponsor

Lead sponsor
Edwards LifesciencesPublic (EW)
Sponsor type
Industry
First posted
Sep 2, 2022

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Collect real-world data on acute and long-term safety and performance of the MITRIS RESILIA Mitral Valve, Model 11400M, in subjects requiring replacement of their native or prosthetic mitral valve with or without concomitant procedures.

Conditions

  • Mitral Stenosis
  • Mitral Valve Insufficiency

Interventions

  • MITRIS RESILIA Mitral Valve, Model 11400MDevice

    Replacement of mitral valve with MITRIS RESLIA Mitral Valve

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Freedom from valve related death or valve related reinterventionTime frame: 1 year
  2. Hemodynamic performance as measured by peak and mean gradient by echocardiographyTime frame: 1 year

Locations

34 sites in 4 countries. Site status is shown where the registry gives one.

  • Hoag Memorial Hospital Presbyterian

    Newport Beach, California

  • Stanford University

    Palo Alto, California

  • AdventHealth Orlando

    Orlando, Florida

31 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.